2025 Global Antibodies Contract Manufacturing Revenue Opportunities Report
Description
The 2025 Global Antibodies Contract Manufacturing Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies Contract Manufacturing by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the global Antibodies Contract Manufacturing market are Lonza Group, WuXi Biologics, Samsung Biologics, and Catalent, Inc. Lonza is a leading Swiss CDMO with extensive capabilities in biologics manufacturing and global facilities, notably serving major pharmaceutical companies. WuXi Biologics, headquartered in China, offers comprehensive end-to-end antibody production with flexible large-scale capacity and advanced expertise in antibody-drug conjugates (ADCs), serving clients worldwide. Samsung Biologics from South Korea is a major manufacturer known for large commercial-scale biologics and monoclonal antibody production. Catalent, an American contract manufacturer, has been expanding its antibody production capacities, including European facility enhancements targeting advanced therapies and bio-based pharmaceuticals.
These companies drive the expanding antibodies contract manufacturing market, which is projected to reach USD 31.76 billion by 2030 with a CAGR of around 10%. Growth is fueled by increasing biopharmaceutical demand for therapeutic antibodies in cancer and chronic diseases, growing adoption of outsourcing by pharmaceutical and biotech firms, and technological innovations like ADC manufacturing that integrate complex biologics and chemical synthesis. These CDMOs maintain global reach, high regulatory compliance, and technical excellence in monoclonal antibody development, purification, and large-scale production, positioning them at the forefront of this rapidly growing pharmaceutical segment.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies Contract Manufacturing by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the global Antibodies Contract Manufacturing market are Lonza Group, WuXi Biologics, Samsung Biologics, and Catalent, Inc. Lonza is a leading Swiss CDMO with extensive capabilities in biologics manufacturing and global facilities, notably serving major pharmaceutical companies. WuXi Biologics, headquartered in China, offers comprehensive end-to-end antibody production with flexible large-scale capacity and advanced expertise in antibody-drug conjugates (ADCs), serving clients worldwide. Samsung Biologics from South Korea is a major manufacturer known for large commercial-scale biologics and monoclonal antibody production. Catalent, an American contract manufacturer, has been expanding its antibody production capacities, including European facility enhancements targeting advanced therapies and bio-based pharmaceuticals.
These companies drive the expanding antibodies contract manufacturing market, which is projected to reach USD 31.76 billion by 2030 with a CAGR of around 10%. Growth is fueled by increasing biopharmaceutical demand for therapeutic antibodies in cancer and chronic diseases, growing adoption of outsourcing by pharmaceutical and biotech firms, and technological innovations like ADC manufacturing that integrate complex biologics and chemical synthesis. These CDMOs maintain global reach, high regulatory compliance, and technical excellence in monoclonal antibody development, purification, and large-scale production, positioning them at the forefront of this rapidly growing pharmaceutical segment.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
